Consensus estimates for SANUWAVE Health (SNWV) project Q3 2026 revenue of $13.75 million and EPS of $0.01, with the stock currently trading near $5.15, far below the $47.00 average analyst price target.
Investors are primarily watching for growth in high-margin recurring applicator and consumable revenue to offset a recent slowdown in capital equipment sales.
The report follows the withdrawal of full-year guidance due to uncertainty regarding CMS reimbursement changes for the UltraMIST system, making Q3 updates critical for visibility into 2027 performance.
Management’s ability to defend gross margins amidst regulatory strain and market saturation for used devices remains a central factor for investor sentiment following recent stock volatility.